Healthcare provider profile · identity verified

Seema Rizvi, DO

Internal Medicine · FAIRFIELD, CA · NPI 1619055423

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	366	134
Amlodipine Besylate	Amlodipine Besylate	321	111
Levothyroxine Sodium	Levothyroxine Sodium	201	60
Albuterol Sulfate Hfa	Albuterol Sulfate	144	63
Atenolol	Atenolol	117	39
Hydrochlorothiazide	Hydrochlorothiazide	112	39
Lisinopril	Lisinopril	111	44
Losartan Potassium	Losartan Potassium	105	35
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	104	24
Metformin Hcl	Metformin Hcl	101	37
Pantoprazole Sodium	Pantoprazole Sodium	101	20
Fluticasone Propionate	Fluticasone Propionate	100	39
Simvastatin	Simvastatin	97	34
Trazodone Hcl	Trazodone Hcl	88	32
Metoprolol Tartrate	Metoprolol Tartrate	86	33
Gabapentin	Gabapentin	79	23
Famotidine	Famotidine	63	21
Tamsulosin Hcl	Tamsulosin Hcl	63	21
Lovastatin	Lovastatin	61	19
Terazosin Hcl	Terazosin Hcl	56	25
Doxycycline Monohydrate	Doxycycline Monohydrate	53	39
Meloxicam	Meloxicam	53	29
Alendronate Sodium	Alendronate Sodium	52	16
Glipizide	Glipizide	50	18
Fluoxetine Hcl	Fluoxetine Hcl	48	13
Ibuprofen	Ibuprofen	47	22
Wixela Inhub	Fluticasone Propion/Salmeterol	46	16
Finasteride	Finasteride	44	14
Montelukast Sodium	Montelukast Sodium	44	14
Nabumetone	Nabumetone	44	23
Ciprofloxacin Hcl	Ciprofloxacin Hcl	41	29
Clopidogrel	Clopidogrel Bisulfate	41	17
Spiriva Respimat	Tiotropium Bromide	41	12
Furosemide	Furosemide	39	14
Alvesco	Ciclesonide	38	19
Metformin Hcl Er	Metformin Hcl	37	16
Potassium Chloride	Potassium Chloride	37	14
Hydrocortisone	Hydrocortisone	35	22
Triamcinolone Acetonide	Triamcinolone Acetonide	34	16
Omeprazole	Omeprazole	32	12
Oxycodone-Acetaminophen	Oxycodone Hcl/Acetaminophen	31	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	29	13
Dicyclomine Hcl	Dicyclomine Hcl	28	suppressed
Cefpodoxime Proxetil	Cefpodoxime Proxetil	27	suppressed
Sertraline Hcl	Sertraline Hcl	27	suppressed
Adacel Tdap	Diph,pertuss(Acell),tet Vac/Pf	26	26
Citalopram Hbr	Citalopram Hydrobromide	26	11
Naproxen	Naproxen	26	11
Advair Hfa	Fluticasone Propion/Salmeterol	25	suppressed
Ondansetron Odt	Ondansetron	25	suppressed
Trospium Chloride	Trospium Chloride	25	suppressed
Carvedilol	Carvedilol	24	suppressed
Venlafaxine Hcl Er	Venlafaxine Hcl	24	suppressed
Bupropion Xl	Bupropion Hcl	23	suppressed
Methocarbamol	Methocarbamol	23	suppressed
Acyclovir	Acyclovir	22	suppressed
Baclofen	Baclofen	22	suppressed
Pravastatin Sodium	Pravastatin Sodium	22	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	21	suppressed
Colchicine	Colchicine	19	suppressed
Nifedipine Er	Nifedipine	19	suppressed
Rosuvastatin Calcium	Rosuvastatin Calcium	19	suppressed
Phenytoin Sodium Extended	Phenytoin Sodium Extended	18	suppressed
Spironolactone	Spironolactone	18	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	17	suppressed
Allopurinol	Allopurinol	17	suppressed
Azelastine Hcl	Azelastine Hcl	17	suppressed
Fenofibrate	Fenofibrate	17	suppressed
Warfarin Sodium	Warfarin Sodium	17	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	15
Verapamil Er	Verapamil Hcl	16	suppressed
Duloxetine Hcl	Duloxetine Hcl	15	suppressed
Cephalexin	Cephalexin	12	12
Humulin N	Insulin Nph Human Isophane	12	suppressed
Metoprolol Succinate	Metoprolol Succinate	12	suppressed
Clonazepam	Clonazepam	11	suppressed
Donepezil Hcl	Donepezil Hcl	11	suppressed
Metoclopramide Hcl	Metoclopramide Hcl	11	suppressed
Metronidazole	Metronidazole	11	suppressed
Nortriptyline Hcl	Nortriptyline Hcl	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error